Clinical Trial

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-19.
Trial Details
NCT Number NCT07607119
Lead Sponsor Samsung Medical Center
Conditions Gastric Adenocarcinoma, Stomach Neoplasms, Locally Advanced Gastric Cancer, Unresectable Gastric Cancer
Enrollment 53 participants
Start Date 2026-05-15
Primary Completion 2028-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-28